Amarantus Bioscience Holdings Inc (AMBS)

Amarantus BioScience Holdings, Inc. is a biopharmaceutical company focused on developing diagnostic and therapeutic product candidates across neurology, psychiatry, ophthalmology, and regenerative medicine. Its pipeline has included LymPro, a blood-based diagnostic under development for Alzheimer’s disease, and MSPrecise, a DNA sequencing assay designed to help identify patients with multiple sclerosis. On the therapeutic side, the company has worked on Eltoprazine for Parkinson’s disease levodopa-induced dyskinesia and attention deficit hyperactivity disorder, as well as mesencephalic-astrocyte-derived neurotrophic factor for use in preclinical and animal-model settings tied to retinal disorders. Additional programs have included NuroPro for neurodegenerative disease diagnostics, BC-SeraPro for oncology diagnostics, PhenoGuard for neurotrophic factor discovery, and Engineered Skin Substitute, a cell therapy-based autologous skin replacement product in mid-stage clinical development for severe burns. The company has also reported research collaborations with the U.S. Army Institute of Surgical Research and Rutgers University. Founded in 2008 and headquartered in New York, New York, it trades as common stock on OTC Markets.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.